KIT and gastrointestinal stromal tumor: On the one hand, imatinib activates CD8+ T cells via inhibition of KIT signaling and reduction of IDO expression; on the other hand, PD1/PD-L1 blockade improves the killing activity of CD8+ T cells against GIST cells [35].